Joint Clinical Study with Massachusetts General Hospital Could Pave the Way for Testing Efficacy of Quantum’s Investigational MS drug, Lucid-21-302TORONTO, June 17, 2025 (GLOBE NEWSWIRE) -- Quantum ...

Researchers have identified structural abnormalities at the myelin-axon interface in Alzheimer's that may hinder electrical ...

New research sheds light on the mechanisms of degeneration in multiple sclerosis, suggesting that mitochondrial dysfunction ...

Multiple sclerosis (MS) affects an estimated 2.3 million people worldwide. Approximately 80% of people with MS have inflammation in the cerebellum, the part of the brain that helps control movement ...

A new study reveals that mitochondrial dysfunction plays a central role in the loss of Purkinje neurons in the cerebellum, ...

An experimental medication boosted motor function in mice and primate models of multiple sclerosis by repairing the myelin ...

Children most affected by MS-related biological aging appeared to be aging up to two years faster than kids without MS, even ...

That uneasy feeling during your morning walk could signal underlying health issues. Changes in pace, balance, or leg ...

Quantum BioPharma (NASDAQ: QNTM) announced plans to issue a special dividend in the form of Contingent Value Rights (“CVRs”) to holders of its Class ...